Jacobio Pharmaceuticals develops first-in-class therapeutics targeting difficult-to-drug oncology pathways using its proprietary drug discovery platforms, including iADC technology. The company focuses on addressing unmet medical needs in cancer treatment through innovative combination therapies and has multiple projects in advanced clinical stages.
Funding
Funding not disclosed
Founders
Product
Problem
Many oncology pathways are considered "difficult-to-drug," limiting the development of effective therapies for various cancers. This lack of targeted treatments results in unmet medical needs and poorer outcomes for cancer patients.
Solution
Jacobio Pharmaceuticals develops first-in-class therapeutics targeting these difficult-to-drug oncology pathways using its proprietary drug discovery platforms, including its iADC (inducible Antibody-Drug Conjugate) technology. The company focuses on innovative combination therapies to address unmet needs in cancer treatment. Jacobio's approach centers around validated tumor signaling pathways, developing novel drugs against challenging targets. Their strategy includes both monotherapy and combination approaches to maximize therapeutic benefit.
Target Audience
The primary target audience includes cancer patients with limited treatment options, oncologists seeking novel therapeutic approaches, and pharmaceutical companies looking for innovative oncology assets.
Features
- iADC technology platform for targeted drug delivery to tumor cells
- Development of novel therapeutics against validated, but difficult-to-drug, oncology targets
- Focus on combination therapies to enhance efficacy and overcome resistance mechanisms
- Pipeline of projects in advanced clinical stages across multiple cancer types
- Targeting of key signaling pathways including P53, RAS, RB, MYC, immune checkpoints, and tumor metabolism
- Proprietary induced allosteric drug discovery platform